Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
DUBLIN, Ireland and TREVOSE, Pa., Feb. 18, 2016 -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that management will be attending SunTrust Robinson Humphrey’s 2016 Orphan Drug Day on February 23, 2016 in New York City.
About Strongbridge Biopharma
Strongbridge Biopharma's strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing's syndrome. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for the treatment of acromegaly and designed to block the synthesis of growth hormone receptor (GHr), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors. COR-003 and COR-005 have received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration, and the Company is pursuing orphan designation for COR-004. Strongbridge Biopharma's intent is to independently commercialize its rare endocrine assets in key global markets.
Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations ICR Inc. Stephanie Carrington +1 646-277-1282 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
